Table 1 Characteristics of pemafibrate interventions included in the present meta-analysis compared with placebo or fenofibrate interventions
No. | References | Year | Region | No. of patients | Age (years) | % women | BMI (kg/m2) | Diabetes (%) | Hypertension (%) | Statin (%) | Study duration (weeks) | TG (mmol/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Ishibashi et al. [11] | 2016 | Japan | 224 | 48 | 2.9 | 26.8 | 11.4 | 25.7 | 0 | 12 | 3.4 |
2 | Arai et al. [17] | 2017 | Japan | 423 | 55 | 20 | 26.2 | 29.3 | 58.5 | 100 | 24 | 4.3 |
3 | Arai et al. [12] | 2018 | Japan | 526 | 49 | 12 | 26.9 | 16.3 | 34.9 | 0 | 12 | 346 (mg/dL) |
4 | Araki et al. [18] | 2018 | Japan | 166 | 61 | 34 | 26 | 100 | 37 | 40.4 | 24 | 3.2 |
5 | Ishibashi et al. [19] | 2018 | Japan | 225 | 53 | 21 | 26.1 | 6.8 | 24.7 | 0 | 24 | 2.7 |
6 | Matsuba et al. [20] | 2018 | Japan | 27 | 46 | 0 | 25.8 | 0 | 18.2 | 0 | 12 | 3.4 |
7 | Yamashita et al. [21] | 2018 | Japan | 32 | 52 | 29 | 25 | 12.5 | 31.3 | 0 | 4 | 2.9 |